CANVAS=Ceftaroline vs Vancomycin in Skin and Skin Structure Infection. CANVAS 1=ABSSSI Trial 1, CANVAS 2=ABSSSI Trial 2.
Additional Day 3 Data from CANVAS Trials: |
65% (13/20) of TEFLARO patients with baseline S. aureus bacteremia demonstrated a clinical response at Day 31 |
In the CANVAS clinical trials, 35% of patients received at least one dose of TEFLARO as OPAT (Outpatient Parenteral Antibiotic Therapy).
Clinical response demonstrated at Day 3 vs the most common pathogens in ABSSSI6 |
||
Integrated CANVAS Day 3 data, % (n/N) | ||
Pathogen | TEFLARO Monotherapy | Vancomycin + aztreonam |
Gram-positive | ||
MSSA | 71.8 (102/142) | 60.1 (92/153) |
MRSA | 81.7 (85/104) | 77.4 (65/84) |
S. pyogenes | 53.2 (25/47) | 57.1 (28/49) |
S. agalactiae | 69.2 (9/13) | 85.7 (6/7) |
Gram-negative | ||
E. coli | 62.5 (5/8) | 53.8 (7/13) |
K. pneumoniae | 55.6 (5/9) | 14.3 (1/7) |
K. oxytoca | 75.0 (6/8) | 50.0 (3/6) |
Clinical response demonstrated at Day 3 vs the most common pathogens in ABSSSI6 | |
Integrated CANVAS Day 3 data, % (n/N) | |
TEFLARO Monotherapy | Vancomycin + aztreonam |
Pathogen | |
Gram-positive | |
MSSA | |
71.8 (102/142) | 60.1 (92/153) |
MRSA | |
81.7 (85/104) | 77.4 (65/84) |
S. pyogenes | |
53.2 (25/47) | 57.1 (28/49) |
S. agalactiae | |
69.2 (9/13) | 85.7 (6/7) |
Gram-negative | |
E. coli | |
62.5 (5/8) | 53.8 (7/13) |
K. pneumoniae | |
55.6 (5/9) | 14.3 (1/7) |
K. oxytoca | |
75.0 (6/8) | 50.0 (3/6) |
These hypothetical case studies present examples of types of patients who may benefit from TEFLARO.
Please also see full Prescribing Information.
Please also see full Prescribing Information.